It was reported in Business Wire that drug therapy for Chronic Back Pain is set to remain as the most profitable sector of the market for chronic back pain relief over the current decade.Drugs for chronic back pain relief and arthritis represented some 57% of the market in 2010 according to the Pharmacor report, with Decision Resources forecasting that the value of the market would remain at around $20b through to 2020.

It’s also likely that new chronic back pain medications will generally be derivatives of existing palliatives.
The report goes on to say that new drugs will represent 18 percent of sales in the chronic pain market during this period, but it is unlikely that they will make up for lost revenues arising from the generic erosion of branded offerings.

These products such as controlled-release oxycodone (Purdue Pharma/Mundipharma/Napp Pharmaceuticals’ OxyContin), Eli Lilly/Boehringer Ingelheim’s Cymbalta/Xeristar, Pfizer’s Lyrica and Celebrex, and the transdermal lidocaine patch (Endo Pharmaceuticals’ Lidoderm, Grunenthal’s Versatis) will all lose market exclusivity by 2020

Read the full Business Wire article

LumbaCurve Lower Back Pain Relief article

How LumbaCurve can offer drug free back pain relief

Video on how LumbaCurve back pain therapy can provide drug free lower back pain relief

An explanation of how the LumbaCurve back pain device can provide an effective drug free lower back pain therapy which could offer back pain relief by Bernard Nolan B.B.Ac.C (UK), a leading practitioner in the ancient healing therapy of Shiatsu

The LumbaCurve back pain relief device is now available in directly through LumbaCurve International or several internet healthcare suppliers including Amazon

As always please consult your GP before using any back pain relief products